
    
      SF1126 is a dual inhibitor of phosphatidylinositol-3-kinase (pan-isoform specific) and
      bromodomain-containing protein 4 (BRD4) which simultaneously disrupts two key MYC-mediating
      factors that promote cancer cell growth.

      Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks
      binding of PD-1 to its ligands PD-L1 and PD-L2. Nivolumab monotherapy is approved in the US
      for HCC previously treated with sorafenib.

      Funding source: FDA OOPD
    
  